FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085563981> ?p ?o ?g. }

• W2085563981 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILProgress in treatments for cancer has improved the prognosis of patients with colorectal cancer. However, there is a strong need for the development of a new intervention therapy that suppresses the occurrence or recurrence effectively with fewer side effects. Immunotherapy may be such a treatment and gene therapy using tumor cells that are genetically modified to produce cytokines has been studied in several therapeutic models. We have previously reported that the interferon (IFN)-α gene-transduced tumor-based vaccination therapy suppresses the outgrowth of established tumors. Although the suppressive effects on established tumors were observed, we did not see reductions in the size of all of the parental tumors. Therefore, further improvements in the treatment are needed before clinical application, we focused on programmed cell death 1 (PD-1), which has been identified as a marker of exhausted T cells. In this study, we evaluated the efficacy of the combination of IFN-γ-transduced tumor cell vaccines and PD-1 blockade, and investigated the mechanisms of the antitumor effects of the combined therapy. A poorly immunogenic murine colorectal cancer cell line, MC38, was transduced to overexpress IFN-γ (MC38-IFNα). In a therapeutic model, parental tumor-bearing mice were inoculated with MC38-IFNα cells and an anti-PD-1 antagonistic antibody. Significant suppression of outgrowth of the established tumors was observed in the IFN-γ and anti-PD-1 combination treatment group (IFN+ anti-PD-1, 174.17 ± 35.54 mm2 vs control, 328.67 ± 26.36 mm2 on day 28, P = 0.0114 vs controls). Immunohistochemical analyses showed marked infiltration of CD4+ cells as well as CD8+ cells in the established tumors of mice treated with both IFN-γ and anti-PD-1. To investigate induction of tumor-specific immune responses, we stimulated splenocytes of IFN-γ or/and anti-PD-1 treated mice twice weekly by DCs in vitro. Significant tumor-specific cytolysis was detected when splenocytes of mice treated with both IFN-γ and anti-PD-1 were used as effector cells (58.1% ± 6.7% for MC38 and 14.1% ± 1.7% for YAC-1, effector:target = 20, P < 0.001). Our findings suggest that blockade of the PD-1 PD-ligand enhanced the Th1-type antitumor immune responses induced by IFN-γ. The combination of IFN-γ gene-transduced tumor cell vaccines and PD-1 blockade may be a possible candidate for a cancer vaccine for clinical trials.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4386. doi:1538-7445.AM2012-4386" @default.
• W2085563981 created "2016-06-24" @default.
• W2085563981 creator A5030187374 @default.
• W2085563981 creator A5040977357 @default.
• W2085563981 creator A5061817630 @default.
• W2085563981 creator A5062452009 @default.
• W2085563981 creator A5074026628 @default.
• W2085563981 creator A5080691959 @default.
• W2085563981 creator A5084274447 @default.
• W2085563981 creator A5089328644 @default.
• W2085563981 creator A5089911766 @default.
• W2085563981 date "2012-04-15" @default.
• W2085563981 modified "2023-09-27" @default.
• W2085563981 title "Abstract 4386: Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death 1 on the growth of established tumors" @default.
• W2085563981 doi "https://doi.org/10.1158/1538-7445.am2012-4386" @default.
• W2085563981 hasPublicationYear "2012" @default.
• W2085563981 type Work @default.
• W2085563981 sameAs 2085563981 @default.
• W2085563981 citedByCount "0" @default.
• W2085563981 crossrefType "proceedings-article" @default.
• W2085563981 hasAuthorship W2085563981A5030187374 @default.
• W2085563981 hasAuthorship W2085563981A5040977357 @default.
• W2085563981 hasAuthorship W2085563981A5061817630 @default.
• W2085563981 hasAuthorship W2085563981A5062452009 @default.
• W2085563981 hasAuthorship W2085563981A5074026628 @default.
• W2085563981 hasAuthorship W2085563981A5080691959 @default.
• W2085563981 hasAuthorship W2085563981A5084274447 @default.
• W2085563981 hasAuthorship W2085563981A5089328644 @default.
• W2085563981 hasAuthorship W2085563981A5089911766 @default.
• W2085563981 hasConcept C104317684 @default.
• W2085563981 hasConcept C111599444 @default.
• W2085563981 hasConcept C121608353 @default.
• W2085563981 hasConcept C126322002 @default.
• W2085563981 hasConcept C1491633281 @default.
• W2085563981 hasConcept C159654299 @default.
• W2085563981 hasConcept C170493617 @default.
• W2085563981 hasConcept C203014093 @default.
• W2085563981 hasConcept C2776178377 @default.
• W2085563981 hasConcept C2777701055 @default.
• W2085563981 hasConcept C2778468042 @default.
• W2085563981 hasConcept C502942594 @default.
• W2085563981 hasConcept C54355233 @default.
• W2085563981 hasConcept C55493867 @default.
• W2085563981 hasConcept C71924100 @default.
• W2085563981 hasConcept C86803240 @default.
• W2085563981 hasConceptScore W2085563981C104317684 @default.
• W2085563981 hasConceptScore W2085563981C111599444 @default.
• W2085563981 hasConceptScore W2085563981C121608353 @default.
• W2085563981 hasConceptScore W2085563981C126322002 @default.
• W2085563981 hasConceptScore W2085563981C1491633281 @default.
• W2085563981 hasConceptScore W2085563981C159654299 @default.
• W2085563981 hasConceptScore W2085563981C170493617 @default.
• W2085563981 hasConceptScore W2085563981C203014093 @default.
• W2085563981 hasConceptScore W2085563981C2776178377 @default.
• W2085563981 hasConceptScore W2085563981C2777701055 @default.
• W2085563981 hasConceptScore W2085563981C2778468042 @default.
• W2085563981 hasConceptScore W2085563981C502942594 @default.
• W2085563981 hasConceptScore W2085563981C54355233 @default.
• W2085563981 hasConceptScore W2085563981C55493867 @default.
• W2085563981 hasConceptScore W2085563981C71924100 @default.
• W2085563981 hasConceptScore W2085563981C86803240 @default.
• W2085563981 hasLocation W20855639811 @default.
• W2085563981 hasOpenAccess W2085563981 @default.
• W2085563981 hasPrimaryLocation W20855639811 @default.
• W2085563981 hasRelatedWork W1496502278 @default.
• W2085563981 hasRelatedWork W1506647723 @default.
• W2085563981 hasRelatedWork W1547259410 @default.
• W2085563981 hasRelatedWork W2003972076 @default.
• W2085563981 hasRelatedWork W2085811812 @default.
• W2085563981 hasRelatedWork W2090475773 @default.
• W2085563981 hasRelatedWork W2394817086 @default.
• W2085563981 hasRelatedWork W2395000660 @default.
• W2085563981 hasRelatedWork W2476562928 @default.
• W2085563981 hasRelatedWork W2482856912 @default.
• W2085563981 hasRelatedWork W2502634075 @default.
• W2085563981 hasRelatedWork W2548114147 @default.
• W2085563981 hasRelatedWork W2566317271 @default.
• W2085563981 hasRelatedWork W2761330261 @default.
• W2085563981 hasRelatedWork W2811277651 @default.
• W2085563981 hasRelatedWork W2897516261 @default.
• W2085563981 hasRelatedWork W2913056591 @default.
• W2085563981 hasRelatedWork W2916176534 @default.
• W2085563981 hasRelatedWork W3080134434 @default.
• W2085563981 hasRelatedWork W3108861527 @default.
• W2085563981 isParatext "false" @default.
• W2085563981 isRetracted "false" @default.
• W2085563981 magId "2085563981" @default.
• W2085563981 workType "article" @default.